August 11, 2022
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Landos Biopharma, Inc.
Registration Statement on Form S-3 (File No. 333-263836), as amended by Amendment No. 1
Request for Acceleration of Effective Date
Requested Date: Monday, August 15, 2022
Requested Time: 8:00 a.m. Eastern Time
Dear Mr. Davis:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263836), as amended by Amendment No. 1 (the Registration Statement) to become effective on August 15, 2022, at 8:00 a.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043, or in her absence, Madison Jones at (202) 728-7087.
|Very truly yours,|
|LANDOS BIOPHARMA, INC.|
|Chief Executive Officer|